A Study to Evaluate Sildenafil for the Treatment of Lymphatic Malformations
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01290484|
Recruitment Status : Completed
First Posted : February 7, 2011
Results First Posted : June 12, 2014
Last Update Posted : June 19, 2015
- Study Details
- Tabular View
- Study Results
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Lymphangioma||Drug: Sildenafil||Phase 1 Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||7 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||An Investigational Pilot Study to Evaluate Sildenafil for the Treatment of Lymphatic Malformations|
|Study Start Date :||December 2010|
|Actual Primary Completion Date :||April 2013|
|Actual Study Completion Date :||December 2013|
Experimental: Open Label
Sildenafil oral tablet three times daily
Sildenafil oral tablet three times daily
- Change in Volume of Lymphatic Malformation [ Time Frame: Baseline, 20 weeks ]Participants were given sildenafil for 20 weeks. Participants weighing more than 20 kg were given 20 mg 3 times daily (60 mg/day). Participants weighing between 8 kg and 20 kg were given 10 mg 3 times daily (30 mg/day).
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||6 Months to 10 Years (Child)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Written informed consent(s) for study participation and (where applicable) the use of the participant's images are obtained according to national regulations from the participant's parent(s) or guardian(s) prior to performing any study procedures.
- The participant is 6 months to 10 years of age at inclusion.
- The participant weight is at least 8kg.
- A diagnosis of LM or mixed venous lymphatic malformation involving the skin and subcutaneous tissue and at least 3cm based on clinical and radiographic criteria.
- LMs may benefit from systemic therapy based on clinical criteria.
- Females must not be pregnant or breast-feeding.
- If participant is a child, parent/guardian must be able to follow instructions and must be willing and able to ensure that the subject is present for all required study visits.
- Subject has no contraindication for use of sildenafil.
- LMs may involve any part of the body.
- Subject will have normal results on screening tests (eye exam, blood tests).
- Subject has no contraindication for MRI examinations, such as metal implants, etc.
- Subject must not be a smoker.
- The participant has a medically unstable health status that may interfere with his/her ability to complete the study.
- The participant presents with one or more of the following medical conditions: hepatic impairment; severe renal impairment; lymphedema conditions such as Milroy disease, Meige lymphedema, Hennekam syndrome, Njolstad syndrome, Aagenaes syndrome, and Fabry disease; hypotension or at risk for hypotension; seizures or history of seizures; any significant cardiovascular risk factors and any condition which requires participants to use nitric oxide donors or nitrates in any form; underlying anatomic or vascular risk factors for developing non-arteritic anterior ischemic optic neuropathy (NAION) including low ocular cup to disc ratio, age over 10, diabetes, hypertension, coronary artery disease, hyperlipidemia, and smoking. (Participants with Down syndrome, Turner syndrome, and Noonan syndrome will be considered on a case-by-case basis).
- The participant has received at least one of the following medications contraindicated in association with sildenafil within 15 days of inclusion: Alprostadil, Azole antifungals, Clarithromycins, Conivaptan, Delavirdine, Erythromycins, Fluvoxamine, Grapefruit, Imatinib, Nefazodone, Nitrates/sodium thiosulfate, Non-selective and selective alpha blockers, Protease inhibitors, Rufinamide, Tadalafil, Telithromycin, Vardenafil, Yohimbe, Yohimbine, Amifostine, Lapatinib, Warfarin
- The participant requires concomitant use of potent cytochrome P450 3A4 inhibitors (such as ketoconazole, itraconazole, erythromycin, saquinavir) or concomitant use of ritonavir.
- The patient has had extensive prior surgery or sclerotherapy to treat LM such that scarring may interfere with the treatment effect of sildenafil.
- The participant has previously been administered treatment for LMs or surgical procedures have been performed to remove the index LMs.
- Participant is currently pregnant or considering becoming pregnant in the next 20 weeks.
- The participant is known to have an allergy to sildenafil.
- Ulcerated or currently infected LMs with pain.
- Diagnosis of the soft tissue tumor as LM is not clinically certain.
- The participant is participating in another clinical study.
- The participant has a history of priapism or is diagnosed with sickle cell anemia or any other disorder which may predispose to priapism.
- The investigator may declare any subject ineligible for a valid medical reason.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01290484
|United States, California|
|Stanford University School of Medicine|
|Stanford, California, United States, 94305|
|Principal Investigator:||Alfred T Lane, MD||Stanford University|
|Responsible Party:||Alfred Lane, Professor of Dermatology and of Pediatrics, Emeritus, Stanford University|
|Other Study ID Numbers:||
UL1TR000093 ( U.S. NIH Grant/Contract )
|First Posted:||February 7, 2011 Key Record Dates|
|Results First Posted:||June 12, 2014|
|Last Update Posted:||June 19, 2015|
|Last Verified:||May 2015|
Lymphatic malformation, vascular malformation
Lymphatic Vessel Tumors
Neoplasms by Histologic Type
Phosphodiesterase 5 Inhibitors
Molecular Mechanisms of Pharmacological Action